These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21816251)

  • 1. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
    Wroblewski K; Sen HN; Yeh S; Faia L; Li Z; Sran P; Gangaputra S; Vitale S; Sherry P; Nussenblatt R
    Can J Ophthalmol; 2011 Aug; 46(4):322-8. PubMed ID: 21816251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
    Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
    Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab for treatment of birdshot chorioretinopathy.
    Sobrin L; Huang JJ; Christen W; Kafkala C; Choopong P; Foster CS
    Arch Ophthalmol; 2008 Feb; 126(2):186-91. PubMed ID: 18268208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
    Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
    J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
    Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
    J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
    Sen HN; Levy-Clarke G; Faia LJ; Li Z; Yeh S; Barron KS; Ryan JG; Hammel K; Nussenblatt RB
    Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis.
    Sella R; Oray M; Friling R; Umar L; Tugal-Tutkun I; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1777-82. PubMed ID: 26228441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].
    Hernández Garfella ML; Díaz Llopis M; Salom Alonso D; Cervera Taulet E
    Arch Soc Esp Oftalmol; 2004 Dec; 79(12):593-8. PubMed ID: 15627927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.
    Heissigerová J; Callanan D; de Smet MD; Srivastava SK; Karkanová M; Garcia-Garcia O; Kadayifcilar S; Ozyazgan Y; Vitti R; Erickson K; Athanikar A; Chu K; Saroj N; Sundaram PA; Varona R; Corp-Dit-Genti V; Buggage R; Cheng Y; Soo Y; Nguyen QD
    Ophthalmology; 2019 Mar; 126(3):428-437. PubMed ID: 30316888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis.
    Hogewind BF; Zijlstra C; Klevering BJ; Hoyng CB
    Eur J Ophthalmol; 2008; 18(3):429-34. PubMed ID: 18465727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.